AcclaimIP-ad

Match Document Document Title
9040706 Pyrrolidine inhibitors of IAP  
The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, Q, X1, X2, Y, R1, R2, R3,...
9040554 Solid forms of nematocidal sulfonamides  
Disclosed are solid forms of 8-chloro-N-[(2-chloro-5-methoxyphenyl)sulfonyl]-6-(trifluoro methyl)-imidazo[1,2-a]pyridine-2-carboxamide (Compound 1). Methods for the preparation of solid forms of...
9029388 Condensed heterocyclic compound  
The present invention provides a compound having a superior PDE10A inhibitory action and use thereof. The compound is a compound represented by the following formula (I): wherein each symbol is as...
9029377 Platelet-activating factor receptor antagonists  
Cyclohexyl sulfonamide compounds which are platelet-activating factor (PAF) receptor antagonists. Said compounds may be useful, for example, for the treatment of atherosclerosis or other...
9018228 Nematocidal sulfonamides  
Disclosed are compounds of Formula 1, N-oxides, and salts thereof, wherein Z is O or S; andR1, R2, R3, Q and n are as defined in the disclosure. Also disclosed are compositions containing the...
9012450 Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation  
Provided are substituted heteroaryl aldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions...
9012042 Condensed-cyclic compound, organic light-emitting device comprising the same, and flat panel display apparatus  
A condensed-cyclic compound represented by Formula 1 below, an organic light-emitting device including the same, and a flat panel display apparatus including the organic light-emitting device: X1,...
9012447 5-HT3 receptor antagonists  
The present invention provides 5-HT3 receptor antagonists of Formula (I): which are useful for the treatment of diseases treatable by inhibition of 5-HT3 receptor such as emesis, pain, drug...
8999966 Compounds that are ERK inhibitors  
Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof, wherein: A is a five membered monocyclic heteroaryl ring; and B is a monocyclic heterocycloalkyl...
8999957 Heterocyclic compounds as ERK inhibitors  
The present invention provides a compound of the Formula I: (Formular I should be inserted here) or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R, R1, R2 and R3 are as...
8993779 Positive allosteric modulators of MGLUR2  
The present invention is directed to benzimidazolone derivatives which are positive allosteric modulators of the mGluR2 receptor, useful in the treatment or prevention of neurological and...
8993590 Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders  
The present invention discloses compounds according to Formula I: Wherein R1a, R1b, R2, R4, R5, R6a, R6b, R7, R8, W, X, Cy, and the subscript a are as defined herein. The present invention relates...
8993612 Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer  
Disclosed are novel calcium release-activated calcium (CRAC) channel inhibitors, methods for preparing them, pharmaceutical compositions containing them, and methods of treatment using them. The...
8980893 Antiparisitic dihydroazole compounds and compositions comprising same  
The present invention relates to novel dihydroazole of formula (I) and salts thereof: Wherein R1, A1, A2, G, X and Y are as defined in the description, compositions thereof, processes for their...
8980888 Pyrazole derivative  
It has been desired to develop a pharmaceutical composition, which is used in agents for preventing and/or treating various diseases related to PDE10 (e.g. mental disorder and neurodegenerative...
8980889 Pyrazole derivative  
It has been desired to develop a pharmaceutical composition, which is used in agents for preventing and/or treating various diseases related to PDE10 (e.g. mental disorder and neurodegenerative...
8980887 2-aryl imidazo[1,2-a]pyridine-3-acetamide derivatives, preparation methods and uses thereof  
Disclosed are 2-arylimidazo[1,2-a]pyridine-3-acetamide derivatives represented by formula I, their tautomer, racemate or optical isomer, their pharmaceutically acceptable salt, or their solvates,...
8975276 Inhibitors of PDE10  
PDE10 inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit PDE10 are also disclosed.
8969567 Nitrogen containing compounds and their use  
Compounds of Formula (I), their preparation and use in preventing or treating bacterial infections are disclosed.
8969570 Beta-lactamase inhibitors  
Aryl substituted diazabicyclooctanes (DBO) compounds that inhibit β-lactamases of class A, class C or class D and potentiate β-lactam antibiotics are disclosed. In particular, this disclosure...
8969566 Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof  
The present invention relates to compounds and processes for preparing compounds of Formula (I), including compounds such as trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-ca rboxamide...
8969565 Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and methods of their use  
Imidazo[1,2-b]pyridazine-based compounds of the formula: are disclosed, wherein R1, R2 and R3 are defined herein. Compositions comprising the compounds and methods of their use to treat, manage...
8969345 Dibenzooxepin derivative  
A dibenzoxepin derivative represented by the following general formula (I) wherein Y is a hydrogen atom and the like, RA is a hydrogen atom and the like, X is the formula (b3) wherein RB is a...
8962844 1,3,4-oxadiazole and 1,3,4-thiadiazole β-lactamase inhibitors  
β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the...
8962843 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors  
β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the...
8957066 Histone deacetylase inhibitors  
This invention relates to generally inhibiting histone deacetylase (“HDAC”) enzymes (e.g., HDAC1, HDAC2, and HDAC3) using compounds of formula (I), wherein the substituents are as defined herein.
8952034 Fused heterocyclic compounds as ion channel modulators  
The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In...
8952004 CXCR3 receptor antagonists  
The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1 to R3, A, B, X, and n are as defined herein. The invention also relates to...
8946426 Substituted bicyclic heterocyclic compounds as gamma secretase modulators  
The present invention is concerned with substituted bicyclic heterocyclic compounds of Formula (I) wherein Het1, Het2, A1, A2, A3 and A4 have the meaning defined in the claims. The compounds...
8946215 Hydroxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use  
The present application relates to novel substituted imidazo[1,2-a]pyridine-3-carboxamides, to processes for their preparation, to their use alone or in combinations for the treatment and/or...
8940897 1,3,4-oxadiazole and 1,3,4-thiadiazole β-lactamase inhibitors  
β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the...
8933232 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors  
β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the...
8933233 1,3,4-oxadiazole and 1,3,4-thiadiazole β-lactamase inhibitors  
β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the...
8933094 Ethynyl compounds useful for treatment of CNS disorder  
The present invention relates to ethynyl compounds of formula wherein X, Y, Z, and R4 are as defined herein or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or...
8927550 Heterocyclic compounds as CCR1 receptor antagonists  
Disclosed are CCR1 receptor antagonists of the formula (I) wherein Ar1, Ar2, R1-R3, X and L are disclosed herein. Also disclosed are compositions, methods of making and using compounds of the...
8927545 Inhibiting Eph B-3 kinase  
EphB3 kinase inhibitor compounds, including certain pyrazolo[1,5-a]pyridine and imidazo[1,2-a]pyridine compounds, inhibit EphB3 kinase. The EphB3 kinase inhibitor compounds can have greater...
8927709 Hepatitis C virus inhibitors  
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus...
8927724 Isoxazole beta-lactamase inhibitors  
β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the...
8916583 Therapeutic compositions for intranasal administration of zolpidem  
The invention provides sprayable aqueous compositions containing zolpidem or single stereoisomer, mixtures of stereoisomers, pharmaceutically acceptable salts or prodrugs thereof, a solubilizing...
8916709 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors  
β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the...
8901149 Imidazo[1,2-a]pyridine derivatives: preparation and pharmaceutical applications  
The present invention relates to hydroxamate compounds which are inhibitors of histone deacetylase. More particularly, the present invention relates to imidazo[1,2-a]pyridine containing compounds...
8901540 Fused ring compounds useful in organic thin-film transistors  
A compound for an organic thin film transistor having a structure represented by the following formula (1): wherein R1 and R2, and R3 and R4 are respectively combined with each other to form an...
8895745 Bicyclic heterocyclic compounds as FGFR inhibitors  
The invention relates to new bicyclic heterocyclic derivative compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases,...
8895313 Ligands for aggregated tau molecules  
Provided are certain benzothiazole, imidazothiazole, imidazopyrimidine and imidazopyridine compounds, including, for example: formula (I) and pharmaceutically and physiologically acceptable salts,...
8889873 Process for the preparation of enantiomerically enriched proton pump inhibitors  
The invention discloses a process for the preparation of compounds having structures typical for proton pump inhibitors in enantiomerically enriched form by using particular metal catalysts in an...
8889868 CC-1065 analogs and their conjugates  
This invention relates to novel analogs of the DNA-alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and...
8889267 Organic light emitting device  
Embodiments of the present invention are directed to a heterocyclic compound and an organic light-emitting device including the heterocyclic compound. The heterocyclic compound is represented by...
8883819 Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension  
Bicyclic heterocyclic derivatives of formula I useful in inhibiting PDGF receptor mediated biological activity. wherein A is and R1, R1a, R2, R3, R4, R5, R6 and X are as defined herein.
8877743 Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors  
A compound of formula (I): wherein: M is hydrogen or a pharmaceutically acceptable salt-forming cation;and R1 and M are as defined herein. Also, methods of treating bacterial infection,...
8871770 Carboxamide compounds and methods for using the same  
Disclosed are carboxamide compounds, as well as pharmaceutical compositions and methods of use. One embodiment is a compound having the structure in which R1, R2, R3, R4, D, J, Z, T, p, q, w and x...